Abstract

IntroductionOne aim of modern pharmacologic treatment in rheumatoid arthritis (RA) is to prevent joint destruction and reduce the need for surgery. Our purpose was to investigate secular trends in the incidence of primary total hip and knee arthroplasties in a well defined sample of patients with RA.MethodsPrevalent cases with RA in 1997 and incident cases from 1997 to 2007 in a community based register in Malmö, south Sweden, were included. Based on a structured review of the medical records, patients were classified according to the 1987 ACR criteria for RA. This cohort was linked to the Swedish Hip Arthroplasty Register (through December 2006) and the Swedish Knee Arthroplasty Register (through October 2007). Patients with a registered total hip or knee arthroplasty before 1997 or before RA diagnosis were excluded. Incidence rates for the period of introduction of TNF inhibitors (1998 to 2001) were compared to the period when biologics were part of the established treatment for severe RA (2002 to 2006/2007).ResultsIn the cohort (n = 2,164; 71% women) a primary hip arthroplasty was registered for 115 patients and a primary knee arthroplasty for 82 patients. The incidence of primary total hip arthroplasties decreased from the period 1998 to 2001 (12.6/1,000 person-years (pyr)) to 2002 to 2006 (6.6/1,000 pyr) (rate ratio (RR) 0.52; 95% confidence interval (CI) 0.35 to 0.76). There was a trend towards an increase of primary knee arthroplasties (incidence 4.8/1,000 pyr vs. 6.8/1,000 pyr; RR 1.43; 95% CI 0.89 to 2.31).ConclusionsOur investigation shows a significant decrease in the incidence of total hip arthroplasties in patients with RA after 2001. Possible explanations include a positive effect on joint damage from more aggressive pharmacological treatment.

Highlights

  • One aim of modern pharmacologic treatment in rheumatoid arthritis (RA) is to prevent joint destruction and reduce the need for surgery

  • In order to do this we studied the incidence of first hip and knee joint arthroplasty in a community setting, using a register containing the majority of patients with RA in this geographical area

  • Subsequent surveys using the diagnostic index of primary care centers and questionnaires sent to other physicians in the area indicate that >90% of all patients with diagnosed RA in the city at that time were included in the register

Read more

Summary

Introduction

One aim of modern pharmacologic treatment in rheumatoid arthritis (RA) is to prevent joint destruction and reduce the need for surgery. Chronic destructive arthritis causes suffering and impaired function for the patient as well as substantial costs for the health care system and society due to increased need for hospital admissions and orthopedic surgery. The aim of pharmacological treatment in RA is to reduce inflammation, improve function and prevent long-term joint damage. Disease-modifying anti-rheumatic drugs (DMARDs), including inhibitors of tumor necrosis factor (TNF) and other biologic immunomodulating agents, are used to reduce inflammation and disease progression. These medications are efficient in many patients, but are costly. Two other studies have shown an overall reduced rate over time of joint surgery in patients with RA [5,6]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call